Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 318, Issue 5, 2020, Pages G870-G888

  Engevik, Melinda A ^a,b   Danhof, Heather A ^a   Chang Graham, Alexandra L ^a   Spinler, Jennifer K ^a,b   Engevik, Kristen A ^a   Herrmann, Beatrice ^a,b   Endres, Bradley T ^c   Garey, Kevin W ^c   Hyser, Joseph M ^a,b   Britton, Robert A ^a   Versalovic, James ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CYSTEINE; MUCIN 2; YEAST EXTRACT; ACTIN-SPECIFIC ADP-RIBOSYLTRANSFERASE, CLOSTRIDIUM; BACTERIAL PROTEIN; BACTERIAL TOXIN; CELL SURFACE RECEPTOR; ENTEROTOXIN; MUC2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ARTICLE; AUTOFLUORESCENCE; CELL VIABILITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; ENTERITIS; ENTEROID; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; JEJUNUM BIOPSY; LIVE CELL IMAGING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE EPITHELIUM; TIME LAPSE IMAGING; VERO CELL LINE; ACTIN FILAMENT; ANIMAL; CELL SHAPE; CHLOROCEBUS AETHIOPS; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; COMPARATIVE STUDY; GENETICS; HELA CELL LINE; HOST PATHOGEN INTERACTION; JEJUNUM; METABOLISM; MICROBIOLOGY; ORGANOID; PATHOGENICITY; PATHOLOGY; TIME FACTOR; ULTRASTRUCTURE; VIRULENCE;

ACTIN CYTOSKELETON; ADP RIBOSE TRANSFERASES; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL SHAPE; CHLOROCEBUS AETHIOPS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTERITIS; ENTEROTOXINS; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; JEJUNUM; MUCIN-2; ORGANOIDS; RECEPTORS, CELL SURFACE; TIME FACTORS; VERO CELLS; VIRULENCE;

EID: 85083545015     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00045.2020     Document Type: Article

References (160)

1. Abid H, Bischof E. An unusual presentation of severe sepsis due to Clostridium difficile enteritis. Cureus 11: e4162, 2019. doi:10.7759/ cureus.4162.
2. Anderson DM, Sheedlo MJ, Jensen JL, Lacy DB. Structural insights into the transition of Clostridioides difficile binary toxin from prepore to pore. Nat Microbiol 5: 102-107, 2020. doi:10.1038/s41564-019-0601-8.
3. Atkinson MH, McLeod BD. Reactive arthritis associated with Clostridium difficile enteritis. J Rheumatol 15: 520-522, 1988.
4. Aujla AK, Averbukh LD, Potashinsky A, Rossi L. A rare case of Clostridium difficile enteritis: a common bug in an uncommon place. Cureus 11: e4519, 2019. doi:10.7759/cureus.4519.
5. Barbieri JT, Riese MJ, Aktories K. Bacterial toxins that modify the actin cytoskeleton. Annu Rev Cell Dev Biol 18: 315-344, 2002. doi:10. 1146/annurev.cellbio.18.012502.134748.
6. Beal EW, Bass R, Harzman AE. Two patients with fulminant Clostridium difficile enteritis who had not undergone total colectomy: a case series and review of the literature. Case Rep Surg 2015: 1-5, 2015. doi:10.1155/2015/957257.
7. Bhargava A, Clifton MS, Mhaske P, Liao M, Pothoulakis C, Leeman SE, Grady EF. Local injection of dsRNA targeting calcitonin receptor-like receptor (CLR) ameliorates Clostridium difficile toxin A-induced ileitis. Proc Natl Acad Sci USA 110: 731-736, 2013. [Erratum in: Proc Natl Acad Sci USA 110: 3651, 2013.] 10.1073/pnas.1219733110.
8. Bhattacharya MK, Niyogi SK, Rasaily R, Bhattacharya SK, Dutta P, Nag A, Pal SC. Clinical manifestation of Clostridium difficile enteritis in Calcutta. J Assoc Physicians India 39: 683-684, 1991.
9. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 40: 1-15, 1998. doi:10.1016/S0195-6701(98)90019-6.
10. Boegh M, Nielsen HM. Mucus as a barrier to drug delivery- understanding and mimicking the barrier properties. Basic Clin Pharmacol Toxicol 116: 179 -186, 2015. doi:10.1111/bcpt.12342.
11. Boetzkes A, Felkel KW, Zeiser J, Jochim N, Just I, Pich A. Secretome analysis of Clostridium difficile strains. Arch Microbiol 194: 675-687, 2012. doi:10.1007/s00203-012-0802-5.
12. Boey CC, Ramanujam TM, Looi LM. Clostridium difficile-related necrotizing pseudomembranous enteritis in association with Henoch-Schonlein purpura. J Pediatr Gastroenterol Nutr 24: 426-429, 1997. doi:10.1097/00005176-199704000-00012.
13. Boku S. [A role of platelet activating factor in experimental hemorrhagic enteritis induced by Clostridium difficile toxin]. Nihon Shokakibyo Gakkai Zasshi 91: 1407-1414, 1994.
14. Boland E, Thompson JS. Fulminant Clostridium difficile enteritis after proctocolectomy and ileal pouch-anal anastamosis. Gastroenterol Res Pract 2008: 1-5, 2008. doi:10.1155/2008/985658.
15. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41, Suppl C: 13-19, doi:10.1093/jac/41.suppl_3.13. 1998.
16. Borriello SP, Ketley JM, Mitchell TJ, Barclay FE, Welch AR, Price AB, Stephen J. Clostridium difficile-a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. J Med Microbiol 24: 53-64, 1987. doi:10. 1099/00222615-24-1-53.
17. Branka JE, Vallette G, Jarry A, Bou-Hanna C, Lemarre P, Van PN, Laboisse CL. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 112: 1887-1894, 1997. doi:10. 1053/gast.1997.v112.pm9178681.
18. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol 20: 313-319, 2012. doi:10.1016/j.tim.2012.04.001.
19. Castagliuolo I, Keates AC, Qiu B, Kelly CP, Nikulasson S, Leeman SE, Pothoulakis C. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci USA 94: 4788-4793, 1997. doi:10. 1073/pnas.94.9.4788.
20. Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT, Pothoulakis C. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol Gastrointest Liver Physiol 273: G333-G341, 1997. doi:10.1152/ajpgi.1997.273.2.G333.
21. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64: 5225-5232, 1996. doi:10.1128/IAI. 64.12.5225-5232.1996.
22. Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg 75: 1203-1206, 2009.
23. Chandrasekaran R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev 41: 723-750, 2017. doi:10.1093/femsre/ fux048.
24. Chang-Graham AL, Danhof HA, Engevik MA, Tomaro-Duchesneau C, Karandikar UC, Estes MK, Versalovic J, Britton RA, Hyser JM. Human intestinal enteroids with inducible neurogenin-3 expression as a novel model of gut hormone secretion. Cell Mol Gastroenterol Hepatol 8: 209-229, 2019. doi:10.1016/j.jcmgh.2019.04.010.
25. Chen P, Tao L, Wang T, Zhang J, He A, Lam KH, Liu Z, He X, Perry K, Dong M, Jin R. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B. Science 360: 664-669, 2018. doi:10.1126/science.aar1999.
26. Chumbler NM, Farrow MA, Lapierre LA, Franklin JL, Lacy DB. Clostridium difficile toxins TcdA and TcdB cause colonic tissue damage by distinct mechanisms. Infect Immun 84: 2871-2877, 2016. doi:10. 1128/IAI.00583-16.
27. Clark GF, Krivan HC, Wilkins TD, Smith DF. Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys 257: 217-229, 1987. doi:10.1016/0003-9861(87)90561-3.
28. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 61: 75-85, 2009. doi:10.1016/j.addr.2008.09.008.
29. Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA, Schwan C, Eichhoff AM, Koch-Nolte F, Lyras D, Aktories K, Minton NP, Petri WA Jr. The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol 1: 16108, 2016. doi:10.1038/nmicrobiol.2016.108.
30. Darling AE, Mau B, Perna NT. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One 5: e11147, 2010. doi:10.1371/journal.pone.0011147.
31. Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 33, Suppl 1: S24 -S28, 2009. doi:10.1016/S0924-8579(09)70012-3.
32. Di Bella S, Ascenzi P, Siarakas S, Petrosillo N, di Masi A. Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins (Basel) 8: 134, 2016. doi:10.3390/toxins8050134.
33. Diebel LN, Liberati DM. Reinforcement of the intestinal mucus layer protects against Clostridium difficile intestinal injury in vitro. J Am Coll Surg 219: 460 -468, 2014. doi:10.1016/j.jamcollsurg.2014.05.005.
34. Dineen SP, Bailey SH, Pham TH, Huerta S. Clostridium difficile enteritis: a report of two cases and systematic literature review. World J Gastrointest Surg 5: 37-42, 2013. doi:10.4240/wjgs.v5.i3.37.
35. Drudy D, Harnedy N, Fanning S, O'Mahony R, Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 13: 298 -304, 2007. doi:10. 1111/j.1469-0691.2006.01634.x.
36. Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, Maragakis LL, Sandora TJ, Weber DJ, Yokoe DS, Gerding DN. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35, Suppl 2: S48-S65, 2014. doi:10.1017/S0899823X00193857.
37. Dupuy B, Sonenshein AL. Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol 27: 107-120, 1998. doi:10.1046/j.1365-2958.1998.00663.x.
38. Edwards AN, Karim ST, Pascual RA, Jowhar LM, Anderson SE, McBride SM. Chemical and stress resistances of Clostridium difficile spores and vegetative cells. Front Microbiol 7: 1698, 2016. doi:10.3389/ fmicb.2016.01698.
39. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest 90: 822-829, 1992. doi:10. 1172/JCI115957.
40. El-Hawiet A, Kitova EN, Kitov PI, Eugenio L, Ng KK, Mulvey GL, Dingle TC, Szpacenko A, Armstrong GD, Klassen JS. Binding of Clostridium difficile toxins to human milk oligosaccharides. Glycobiology 21: 1217-1227, 2011. doi:10.1093/glycob/cwr055.
41. El-Hawiet A, Kitova EN, Klassen JS. Recognition of human milk oligosaccharides by bacterial exotoxins. Glycobiology 25: 845-854, 2015. doi:10.1093/glycob/cwv025.
42. El Muhtaseb MS, Apollos JK, Dreyer JS. Clostridium difficile enteritis: a cause for high ileostomy output. ANZ J Surg 78: 416, 2008. doi:10.1111/j.1445-2197.2008.04494.x.
43. Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR, Worrell RT. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol 308: G497-G509, 2015. doi:10.1152/ajpgi. 00090.2014.
44. Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT. Human Clostridium difficile infection: altered mucus production and composition. Am J Physiol Gastrointest Liver Physiol 308: G510 -G524, 2015. doi:10.1152/ajpgi.00091.2014.
45. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, Kou B, Opekun AR, Burrin D, Graham DY, Ramani S, Atmar RL, Estes MK. Replication of human noroviruses in stem cell-derived human enteroids. Science 353: 1387-1393, 2016. doi:10.1126/science.aaf5211.
46. Eveillard M, Fourel V, Bare MC, Kernéis S, Coconnier MH, Karjalainen T, Bourlioux P, Servin AL. Identification and characterization of adhesive factors of Clostridium difficile involved in adhesion to human colonic enterocyte-like Caco-2 and mucus-secreting HT29 cells in culture. Mol Microbiol 7: 371-381, 1993. doi:10.1111/j.1365-2958.1993. tb01129.x.
47. Fiorentini C, Donelli G, Nicotera P, Thelestam M. Clostridium difficile toxin A elicits Ca(2+)-independent cytotoxic effects in cultured normal rat intestinal crypt cells. Infect Immun 61: 3988 -3993, 1993. doi:10. 1128/IAI.61.9.3988-3993.1993.
48. Fiorentini C, Thelestam M. Clostridium difficile toxin A and its effects on cells. Toxicon 29: 543-567, 1991. doi:10.1016/0041-0101(91)90050-2.
49. Fleming F, Khursigara N, O'Connell N, Darby S, Waldron D. Fulminant small bowel enteritis: a rare complication of Clostridium difficile-associated disease. Inflamm Bowel Dis 15: 801-802, 2009. doi: 10.1002/ibd.20758.
50. Follmar KE, Condron SA, Turner II, Nathan JD, Ludwig KA. Treatment of metronidazole-refractory Clostridium difficile enteritis with vancomycin. Surg Infect (Larchmt) 9: 195-200, 2008. doi:10.1089/sur. 2006.089.
51. Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Ettayebi K, Blutt SE, Hyser JM, Zeng XL, Crawford SE, Broughman JR, Estes MK, Donowitz M. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood) 239: 1124-1134, 2014. doi:10.1177/1535370214529398.
52. Foulke-Abel J, In J, Yin J, Zachos NC, Kovbasnjuk O, Estes MK, de Jonge H, Donowitz M. Human enteroids as a model of upper small intestinal ion transport physiology and pathophysiology. Gastroenterology 150: 638-649.e8, 2016. doi:10.1053/j.gastro.2015.11.047.
53. Freiler JF, Durning SJ, Ender PT. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis 33: 1429 -1431, 2001. doi:10.1086/322675.
54. Gagandeep D, Ira S. Clostridium difficile enteritis 9 years after total proctocolectomy: a rare case report. Am J Gastroenterol 105: 962-963, 2010. doi:10.1038/ajg.2009.680.
55. Genth H, Dreger SC, Huelsenbeck J, Just I. Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 40: 592-597, 2008. doi:10.1016/j.biocel.2007.12.014.
56. Gerding DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5: 15-27, 2014. doi:10.4161/gmic.26854.
57. Gomez-Trevino M, Boureau H, Karjalainen T, Bourlioux P. Clostridium difficile Adherence to Mucus: Results of an in vivo and ex vivo Assay. Microb Ecol Health Dis 9: 329-334, 1996. doi:10.1002/ (SICI)1234-987X(199611)9:6<329:AID-MEH329>3.3.CO;2-C.
58. Greco A, Ho JG, Lin SJ, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol 13: 460-461, 2006. doi:10.1038/nsmb1084.
59. Guillemin P, Gerster JC. [Reactive arthritis induced by Clostridium difficile enteritis]. Praxis (Bern 1994) 94: 471-474, 2005. doi:10.1024/ 0369-8394.94.12.471.
60. Gupta P, Zhang Z, Sugiman-Marangos SN, Tam J, Raman S, Julien JP, Kroh HK, Lacy DB, Murgolo N, Bekkari K, Therien AG, Hernandez LD, Melnyk RA. Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants. J Biol Chem 292: 17290 -17301, 2017. doi:10.1074/jbc.M117.806687.
61. Hariri S, Gouin P, Tuech JJ, Veber B, Dureuil B. Clostridium difficile infection causing multiple organ failure and small-bowel enteritis. Clin Res Hepatol Gastroenterol 35: 142-144, 2011. doi:10.1016/j.clinre. 2010.10.004.
62. Hartley-Tassell LE, Awad MM, Seib KL, Scarselli M, Savino S, Tiralongo J, Lyras D, Day CJ, Jennings MP. Lectin activity of the TcdA and TcdB toxins of Clostridium difficile. Infect Immun 87: e00676-18, 2019. doi:10.1128/IAI.00676-18.
63. Hasnain SZ, Evans CM, Roy M, Gallagher AL, Kindrachuk KN, Barron L, Dickey BF, Wilson MS, Wynn TA, Grencis RK, Thornton DJ. Muc5ac: a critical component mediating the rejection of enteric nematodes. J Exp Med 208: 893-900, 2011. doi:10.1084/jem.20102057.
64. Hayetian FD, Read TE, Brozovich M, Garvin RP, Caushaj PF. Ileal perforation secondary to Clostridium difficile enteritis: report of 2 cases. Arch Surg 141: 97-99, 2006. doi:10.1001/archsurg.141.1.97.
65. He D, Sougioultzis S, Hagen S, Liu J, Keates S, Keates AC, Pothoulakis C, Lamont JT. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology 122: 1048-1057, 2002. doi:10.1053/gast.2002.32386.
66. Hecht G, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 82: 1516 - 1524, 1988. doi:10.1172/JCI113760.
67. Hemmasi S, Czulkies BA, Schorch B, Veit A, Aktories K, Papatheodorou P. Interaction of the Clostridium difficile binary toxin CDT and its host cell receptor, lipolysis-stimulated lipoprotein receptor (LSR). J Biol Chem 290: 14031-14044, 2015. doi:10.1074/jbc.M115.650523.
68. Ho JG, Greco A, Rupnik M, Ng KK. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci USA 102: 18373-18378, 2005. doi:10.1073/pnas.0506391102.
69. Hundsberger T, Braun V, Weidmann M, Leukel P, Sauerborn M, von Eichel-Streiber C. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244: 735-742, 1997. doi:10.1111/j.1432-1033.1997.t01-1-00735.x.
70. Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 80: 88 -101, 2001. doi:10. 1097/00005792-200103000-00002.
71. Jank T, Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16: 222-229, 2008. doi:10.1016/j.tim.2008.01.011.
72. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17: 15R-22R, 2007. doi:10.1093/glycob/cwm004.
73. Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 10: 352-361, 2013. doi:10.1038/nrgastro.2013.35.
74. Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 51: 2883-2887, 2007. doi:10.1128/AAC. 01443-06.
75. Juntunen M, Kirjavainen PV, Ouwehand AC, Salminen SJ, Isolauri E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 8: 293-296, 2001. doi:10.1128/CDLI.8.2.293-296.2001.
76. Just I, Selzer J, von Eichel-Streiber C, Aktories K. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest 95: 1026-1031, 1995. doi:10.1172/JCI117747.
77. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Aktories K. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 270: 13932-13936, 1995. doi:10.1074/jbc.270.23.13932.
78. Karasawa T, Maegawa T, Nojiri T, Yamakawa K, Nakamura S. Effect of arginine on toxin production by Clostridium difficile in defined medium. Microbiol Immunol 41: 581-585, 1997. doi:10.1111/j.1348-0421.1997.tb01895.x.
79. Karjalainen T, Barc MC, Collignon A, Trollé S, Boureau H, Cotte-Laffitte J, Bourlioux P. Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun 62: 4347-4355, 1994. doi:10.1128/IAI.62.10.4347-4355. 1994.
80. Karlsson S, Burman LG, Åkerlund T. Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145: 1683-1693, 1999. doi:10.1099/13500872-145-7-1683.
81. Karlsson S, Lindberg A, Norin E, Burman LG, Akerlund T. Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile. Infect Immun 68: 5881-5888, 2000. doi:10.1128/IAI.68.10.5881-5888.2000.
82. Kavanaugh NL, Zhang AQ, Nobile CJ, Johnson AD, Ribbeck K. Mucins suppress virulence traits of Candida albicans. MBio 5: e01911-14, 2014. doi:10.1128/mBio.01911-14.
83. Keel MK, Songer JG. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet Pathol 44: 814-822, 2007. doi:10.1354/vp.44-6-814.
84. Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 93: 1257-1265, 1994. doi:10.1172/JCI117080.
85. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, LaMont JT. Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem 280: 21237-21245, 2005. doi:10.1074/jbc.M413842200.
86. Kim JH, Muder RR. Clostridium difficile enteritis: a review and pooled analysis of the cases. Anaerobe 17: 52-55, 2011. doi:10.1016/j.anaerobe. 2011.02.002.
87. Kim KA, Wry P, Hughes E Jr, Butcher J, Barbot D. Clostridium difficile small-bowel enteritis after total proctocolectomy: a rare but fatal, easily missed diagnosis. Report of a case. Dis Colon Rectum 50: 920 - 923, 2007. doi:10.1007/s10350-006-0784-y.
88. Köksal F. [The role of Clostridium difficile in antibiotic-associated enteritis]. Mikrobiyol Bul 19: 109-111, 1985.
89. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother 57: 3214 -3223, 2013. doi:10.1128/AAC. 02633-12.
90. Kovbasnjuk O, Zachos NC, In J, Foulke-Abel J, Ettayebi K, Hyser JM, Broughman JR, Zeng XL, Middendorp S, de Jonge HR, Estes MK, Donowitz M. Human enteroids: preclinical models of non-inflammatory diarrhea. Stem Cell Res Ther 4, Suppl 1: S3, 2013. doi:10.1186/ scrt364.
91. Kralovich KA, Sacksner J, Karmy-Jones RA, Eggenberger JC. Pseudomembranous colitis with associated fulminant ileitis in the defunctionalized limb of a jejunal-ileal bypass. Report of a case. Dis Colon Rectum 40: 622-624, 1997. doi:10.1007/BF02055391.
92. Krivan HC, Clark GF, Smith DF, Wilkins TD. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun 53: 573-581, 1986. doi:10.1128/IAI.53.3.573-581.1986.
93. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467: 711-713, 2010. doi:10.1038/nature09397.
94. Kuntz DP, Shortsleeve MJ, Kantrowitz PA, Gauvin GP. Clostridium difficile enteritis. A cause of intramural gas. Dig Dis Sci 38: 1942-1944, 1993. doi:10.1007/BF01296124.
95. Kuribayashi H, Miyata M, Yamakawa H, Yoshinari K, Yamazoe Y. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol 697: 132-138, 2012. doi:10.1016/j.ejphar.2012.09.048.
96. Kurtz LE, Yang SS, Bank S. Clostridium difficile-associated small bowel enteritis after total proctocolectomy in a Crohn's disease patient. J Clin Gastroenterol 44: 76-77, 2010. doi:10.1097/MCG. 0b013e3181a7481b.
97. LaFrance ME, Farrow MA, Chandrasekaran R, Sheng J, Rubin DH, Lacy DB. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity. Proc Natl Acad Sci USA 112: 7073-7078, 2015. doi:10.1073/pnas.1500791112.
98. Lamont JT, Trnka YM, Lamont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 315: 381-383, 1980. doi:10.1016/S0140-6736(80)90939-3.
99. Lavallée C, Laufer B, Pépin J, Mitchell A, Dubé S, Labbé AC. Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin Microbiol Infect 15: 1093-1099, 2009. doi:10.1111/j.1469-0691.2009.03004.x.
100. Lawley TD, Croucher NJ, Yu L, Clare S, Sebaihia M, Goulding D, Pickard DJ, Parkhill J, Choudhary J, Dougan G. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol 191: 5377-5386, 2009. doi:10.1128/JB.00597-09.
101. Leslie JL, Huang S, Opp JS, Nagy MS, Kobayashi M, Young VB, Spence JR. Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect Immun 83: 138-145, 2015. doi:10. 1128/IAI.02561-14.
102. Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 11: 138 -142, 2007. doi:10.1007/s11605-006-0022-x.
103. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. Toxin B is essential for virulence of Clostridium difficile. Nature 458: 1176-1179, 2009. doi:10.1038/nature07822.
104. MacDonald KS, McLeod J, Nicolle L. Clostridium difficile enteritis in a Canadian tertiary care hospital. Can J Infect Control 8: 37-40, 1993.
105. Mahida YR, Galvin A, Makh S, Hyde S, Sanfilippo L, Borriello SP, Sewell HF. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun 66: 5462-5469, 1998. doi:10.1128/IAI.66.11. 5462-5469.1998.
106. Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection-an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum 46: 267-270, 2003. doi:10.1007/s10350-004-6533-1.
107. May M, Wang T, Müller M, Genth H. Difference in F-actin depolymerization induced by toxin B from the Clostridium difficile strain VPI 10463 and toxin B from the variant Clostridium difficile serotype F strain 1470. Toxins (Basel) 5: 106 -119, 2013. doi:10.3390/ toxins5010106.
108. McBride M. Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Clin Infect Dis 21: 455, 1995. doi:10.1093/clinids/ 21.2.455.
109. Miller DL, Sedlack JD, Holt RW. Perforation complicating rifampinassociated pseudomembranous enteritis. Arch Surg 124: 1082, 1989. doi:10.1001/archsurg.1989.01410090092020.
110. Mitchell MJ, Laughon BE, Lin S. Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect Immun 55: 1610-1615, 1987. doi:10.1128/IAI.55.7.1610-1615.1987.
111. Na X, Kim H, Moyer MP, Pothoulakis C, LaMont JT. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun 76: 2862-2871, 2008. doi:10.1128/IAI. 00326-08.
112. Na X, Zhao D, Koon HW, Kim H, Husmark J, Moyer MP, Pothoulakis C, LaMont JT. Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 128: 1002-1011, 2005. doi:10.1053/j.gastro.2005.01. 053.
113. Nasser H, Munie S, Shakaroun D, Ivanics T, Nalamati S, Killu K. Clostridium difficile Enteritis after total abdominal colectomy for ulcerative colitis. Case Rep Crit Care 2019: 1-4, 2019. doi:10.1155/2019/ 2987682.
114. Navaneethan U, Giannella RA. Thinking beyond the colon-small bowel involvement in Clostridium difficile infection. Gut Pathog 1: 7, 2009. doi:10.1186/1757-4749-1-7.
115. Oka S, Inamatsu T, Urayama K, Shimada K. [Adverse effects of antimicrobiological agents and countermeasures-Clostridium difficile enteritis: with special reference to early diagnosis]. Nihon Rinsho 44: 951-954, 1986.
116. Olson A, Diebel LN, Liberati DM. Effect of host defenses on Clostridium difficile toxin-induced intestinal barrier injury. J Trauma Acute Care Surg 74: 983-990, 2013. doi:10.1097/TA.0b013e3182858477.
117. Ouwehand AC, Isolauri E, Kirjavainen PV, Salminen SJ. Adhesion of four Bifidobacterium strains to human intestinal mucus from subjects in different age groups. FEMS Microbiol Lett 172: 61-64, 1999. doi:10. 1111/j.1574-6968.1999.tb13450.x.
118. Papatheodorou P, Carette JE, Bell GW, Schwan C, Guttenberg G, Brummelkamp TR, Aktories K. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci USA 108: 16422-16427, 2011. doi:10.1073/pnas.1109772108.
119. Papatheodorou P, Hornuss D, Nölke T, Hemmasi S, Castonguay J, Picchianti M, Aktories K. Clostridium difficile binary toxin CDT induces clustering of the lipolysis-stimulated lipoprotein receptor into lipid rafts. MBio 4: e00244-13, 2013. doi:10.1128/mBio.00244-13.
120. Parikh VA, Edlund JW. Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol 22: 329, 1996. doi:10.1097/ 00004836-199606000-00022.
121. Peacock O, Speake W, Shaw A, Goddard A. Clostridium difficile enteritis in a patient after total proctocolectomy. BMJ Case Rep 2009: bcr10.20008.1165, 2009. doi:10.1136/bcr.10.2008.1165.
122. Perry JL, Ramachandran NK, Utama B, Hyser JM. Use of genetically-encoded calcium indicators for live cell calcium imaging and localization in virus-infected cells. Methods 90: 28-38, 2015. doi:10. 1016/j.ymeth.2015.09.004.
123. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADPribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56: 2299-2306, 1988. doi:10.1128/IAI.56.9.2299-2306.1988.
124. Pothoulakis C, Galili U, Castagliuolo I, Kelly CP, Nikulasson S, Dudeja PK, Brasitus TA, LaMont JT. A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. Gastroenterology 110: 1704-1712, 1996. doi:10. 1053/gast.1996.v110.pm8964394.
125. Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Desai HP, Wilkins TD, LaMont JT. Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest 98: 641-649, 1996. doi:10.1172/JCI118835.
126. Ramos Martínez A, Romero Pizarro Y, Martínez Arrieta F, Balandín Moreno B, Múñez Rubio E, Cuiñas León K, Sánchez Romero I, Cantos López de Ibargüen B, Asensio Vegas A. [Clostridium difficile enteritis]. Gastroenterol Hepatol 34: 539-545, 2011. doi: 10.1016/j.gastrohep.2011.03.005.
127. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47: 241-259, 2006. doi:10.1194/ jlr.R500013-JLR200.
128. Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M, Bradke F, Jenne D, Holak TA, Werb Z, Sixt M, Wedlich-Soldner R. Lifeact: a versatile marker to visualize F-actin. Nat Methods 5: 605-607, 2008. doi:10.1038/nmeth.1220.
129. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, Cosentini E, Feil W, Schiessel R, LaMont JT. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95: 2004-2011, 1995. doi:10.1172/ JCI117885.
130. Riegler M, Sedivy R, Sogukoglu T, Castagliuolo I, Pothoulakis C, Cosentini E, Bischof G, Hamilton G, Teleky B, Feil W, Lamont JT, Wenzl E. Epidermal growth factor attenuates Clostridium difficile toxin A- and B-induced damage of human colonic mucosa. Am J Physiol Gastrointest Liver Physiol 273: G1014 -G1022, 1997. doi:10.1152/ajpgi. 1997.273.5.G1014.
131. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141: 1762-1772, 2011. doi:10.1053/j.gastro.2011.07.050.
132. Saxena K, Blutt SE, Ettayebi K, Zeng XL, Broughman JR, Crawford SE, Karandikar UC, Sastri NP, Conner ME, Opekun AR, Graham DY, Qureshi W, Sherman V, Foulke-Abel J, In J, Kovbasnjuk O, Zachos NC, Donowitz M, Estes MK. Human intestinal enteroids: a new model to study human rotavirus infection, host restriction, and pathophysiology. J Virol 90: 43-56, 2016. doi:10.1128/JVI.01930-15.
133. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist. Cell Metab 17: 225-235, 2013. doi:10.1016/j.cmet.2013.01.003.
134. Semenyuk EG, Poroyko VA, Johnston PF, Jones SE, Knight KL, Gerding DN, Driks A. Analysis of bacterial communities during Clostridium difficile infection in the mouse. Infect Immun 83: 4383-4391, 2015. doi:10.1128/IAI.00145-15.
135. Shortland JR, Spencer RC, Williams JL. Pseudomembranous colitis associated with changes in an ileal conduit. J Clin Pathol 36: 1184 -1187, 1983. doi:10.1136/jcp.36.10.1184.
136. Siddiqui J, Campion T, Wei R, Kuzmich S. Clostridium difficile enteritis: diffuse small bowel radiological changes in a patient with abdominal sepsis. BMJ Case Rep 2018: bcr-2017-222209, 2018. doi:10. 1136/bcr-2017-222209.
137. Söderlin MK, Alasaarela E, Hakala M. Reactive arthritis induced by Clostridium difficile enteritis as a complication of Helicobacter pylori eradication. Clin Rheumatol 18: 337-338, 1999. doi:10.1007/ s100670050113.
138. Sorg JA, Sonenshein AL. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192: 4983-4990, 2010. doi:10.1128/JB.00610-10.
139. Steele J, Chen K, Sun X, Zhang Y, Wang H, Tzipori S, Feng H. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis 205: 384-391, 2012. doi:10.1093/infdis/jir748.
140. Tao L, Zhang J, Meraner P, Tovaglieri A, Wu X, Gerhard R, Zhang X, Stallcup WB, Miao J, He X, Hurdle JG, Breault DT, Brass AL, Dong M. Frizzled proteins are colonic epithelial receptors for C. difficile toxin B. Nature 538: 350-355, 2016. doi:10.1038/nature19799.
141. Testore GP, Nardi F, Babudieri S, Giuliano M, Di Rosa R, Panichi G. Isolation of Clostridium difficile from human jejunum: identification of a reservoir for disease? J Clin Pathol 39: 861-862, 1986. doi:10.1136/jcp. 39.8.861.
142. Thai H, Guerron AD, Bencsath KP, Liu X, Loor M. Fulminant Clostridium difficile enteritis causing abdominal compartment syndrome. Surg Infect (Larchmt) 15: 821-825, 2014. doi:10.1089/sur.2013.026.
143. Theriot CM, Bowman AA, Young VB. Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. MSphere 1: e00045-15, 2016. doi:10.1128/mSphere.00045-15.
144. Tjandra JJ, Street A, Thomas RJ, Gibson R, Eng P, Cade J. Fatal Clostridium difficile infection of the small bowel after complex colorectal surgery. ANZ J Surg 71: 500 -503, 2001. doi:10.1046/j.1440-1622.2001. 02083.x.
145. Tjellström B, Stenhammar L, Eriksson S, Magnusson KE. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 341: 701-702, 1993. doi:10.1016/0140-6736(93)90477-X.
146. Triadafilopoulos G, Pothoulakis C, O'Brien MJ, LaMont JT. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93: 273-279, 1987. doi:10.1016/0016-5085(87)91014-6.
147. Tsutaoka B, Hansen J, Johnson D, Holodniy M. Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Clin Infect Dis 18: 982-984, 1994. doi:10.1093/clinids/18.6.982.
148. Tucker KD, Wilkins TD. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 59: 73-78, 1991. doi:10.1128/IAI.59.1.73-78.1991.
149. Valdés L, Gueimonde M, Ruas-Madiedo P. Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29. J Microbiol Methods 119: 66 -73, 2015. doi:10.1016/j.mimet. 2015.09.022.
150. VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, Ciorba MA, Stappenbeck TS. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut 64: 911-920, 2015. doi:10.1136/gutjnl-2013-306651.
151. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum 43: 551-554, 2000. doi:10.1007/BF02237205.
152. Vrieze A, Out C, Fuentes S, Jonker L, Reuling I, Kootte RS, van Nood E, Holleman F, Knaapen M, Romijn JA, Soeters MR, Blaak EE, Dallinga-Thie GM, Reijnders D, Ackermans MT, Serlie MJ, Knop FK, Holst JJ, van der Ley C, Kema IP, Zoetendal EG, de Vos WM, Hoekstra JB, Stroes ES, Groen AK, Nieuwdorp M. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 60: 824-831, 2014. doi:10.1016/j.jhep.2013.11. 034.
153. Wada Y, Satoh T, Kubo M. [5 cases of Clostridium difficile enteritis in infants]. Kansenshogaku Zasshi 69: 608 -614, 1995. doi:10.11150/ kansenshogakuzasshi1970.69.608.
154. Wee B, Poels JA, McCafferty IJ, Taniere P, Olliff J. A description of CT features of Clostridium difficile infection of the small bowel in four patients and a review of literature. Br J Radiol 82: 890-895, 2009. doi:10.1259/bjr/57970083.
155. Wood MJ, Hyman N, Hebert JC, Blaszyk H. Catastrophic Clostridium difficile enteritis in a pelvic pouch patient: report of a case. J Gastrointest Surg 12: 350 -352, 2008. doi:10.1007/s11605-007-0440-4.
156. Yafi FA, Selvasekar CR, Cima RR. Clostridium difficile enteritis following total colectomy. Tech Coloproctol 12: 73-74, 2008.
157. Yee HF Jr, Brown RS Jr, Ostroff JW. Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol 22: 45-47, 1996. doi:10.1097/00004836-199601000-00013.
158. Zachos NC, Kovbasnjuk O, Foulke-Abel J, In J, Blutt SE, de Jonge HR, Estes MK, Donowitz M. Human enteroids/colonoids and intestinal organoids functionally recapitulate normal intestinal physiology and pathophysiology. J Biol Chem 291: 3759-3766, 2016. doi:10.1074/jbc. R114.635995.
159. Zhang S, Palazuelos-Munoz S, Balsells EM, Nair H, Chit A, Kyaw MH. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis 16: 447, 2016. doi:10.1186/s12879-016-1786-6.
160. Zoppi G, Vinco A, Cinquetti M, Barbato G, Luciano A. [A case of slowly resolving enteritis caused by Clostridium difficile]. Pediatr Med Chir 17: 459-460, 1995.